

RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

PAPER

An efficient aqueous phase synthesis of benzimidazoles/benzothiazoles in the presence of β -cyclodextrin.

Ramesh Katla,^a Rakhi Chowrasia,^b Padma Sunitha Manjari,^b Nelson Luís C. Domingues.^{a*}

Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX


DOI: 10.1039/b000000x

Benzimidazoles/benzothiazoles were synthesized in water under neutral conditions by the reaction of aromatic aldehydes, *o*-phenylenediamine/2-amino thiophenol mediated by β -cyclodextrin in high yields. β -Cyclodextrin can be recovered and reused without significant loss of activity.

Introduction


Benzimidazole/benzothiazole moieties are important scaffolds in pharmaceutical applications, associated with a wide variety of medicinal, biological activities such as antifungal, antiviral, antibacterial, anticancer, anti-inflammatory, antiulcer, antihypertensive, antihistaminic, anticonvulsant, and antiparkinsonian activities.^[1-3] In addition, their analogues exhibit significant activity against several viruses, such as HIV, herpes (HSV-1), RNA influenza and human cytomegalovirus (HCMV).⁴ They are also widely used in organic synthesis as intermediates. Especially benzimidazoles are useful in controlling the diseases such as hypertension,⁵ ischemia-reperfusion injury,⁶ as well as obesity.⁷ There are numerous drugs containing benzimidazole/benzothiazole skeletons as shown in Figure 1. Several methodologies have been developed for the synthesis of benzimidazole/benzothiazoles. Mirkhani *et al.* has reported the synthesis of 2-imidazolines and bis-imidazolines by the reaction of ethylenediamine, and nitriles in the presence of sulfur under ultrasonic irradiation.⁸ Das *et al.* described benzimidazoles from 1,2-phenylenediamine, with aldehydes by using (bromodimethyl)sulfonium bromide at room temperature.⁹ Hornberger has developed one-pot synthesis of disubstituted benzimidazoles from 2-nitro anilines with palladium charcoal as a catalyst in the presence of trimethyl orthoformate and catalytic pyridinium *p*-toluenesulfonate (PPTS) at rt.¹⁰ Lin and co-workers synthesized some benzimidazoles from phenylenediamines, and aldehydes, in the presence of molecular iodine.¹¹ Pierre L. Beaulieu *et al* demonstrated the oxone mediated

50 benzimidazoles, benzoxazoles and benzothiazoles by using phenylene diamines/2-amino thiophenol/2-amino thiol and acid one-pot synthesis of benzimidazoles using 1,2-phenylenediamines, and aldehydes in wet DMF at rt.¹² Srinivasan and co-workers developed the synthesis of 2-aryl chlorides under ambient conditions using ionic liquids, 1-butylimidazolium tetrafluoroborate [Hbim]BF₄ and 1,3-di-n-butylimidazolium tetrafluoroborate ([bbim]BF₄).¹³



60 **Figure 1.** Some marketed drugs with benzimidazole/benzothiazole skeleton.

Ranu *et al.* described the synthesis of 2-substituted benzimidazoles by using *o*-phenylenediamine with aromatic aldehydes in the presence of an ionic liquid, 1-methyl-3-pentylimidazolium tetrafluoroborate, [pmim]BF₄ at room temperature.¹⁴



70 **Scheme 1.** Synthesis of benzothiazoles/benzimidazoles.

However, the above mentioned methods have been associated with different draw backs such as the use of hazardous organic solvents, strongly acidic conditions, expensive moisture-sensitive catalysts, or tedious workup conditions as well as low yields. In continuation of our efforts towards the development of novel environmentally benign methodologies,¹⁵ herein we report an

^aOrganic Catalysis and Biocatalysis Laboratory OCBL/ FACET, Federal University of Grande Dourados—UFGD, Dourados/Itahúm rod. km 12

45 s/n, Zip Code 79804-970, Dourados, MS, Brazil.

^bDepartment of Chemistry, Osmania University, Hyderabad, India-500004.

E-mail: nelsondomingues@ufgd.edu.br

† Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/b000000x/

efficient one-pot protocol for the synthesis of benzimidazole/benzothiazole derivatives by a two-component reaction, involving 1,2-diamino benzene/2-amino thiophenol for the first time promoted by recyclable β -CD in aqueous medium (Scheme 1). Presently organic reactions in aqueous phase have attracted the attention of researchers because of the added advantages of water, as an eco-friendly and economically affordable solvent. However, the fundamental problem in performing the reactions in water is that many organic substrates are hydrophobic and are insoluble in aqueous medium.

Results and Discussion

Cyclodextrins (CDs) are cyclic oligosaccharides possessing hydrophobic cavities, which bind substrates selectively and catalyze the chemical reactions with high selectivity. They promote the reactions by supramolecular catalysis involving reversible formation of host-guest complexation by non-covalent bonding. We describe, herein, the synthesis of 2-substituted benzimidazoles/benzothiazoles demonstrating the remarkable catalytic activity of β -cyclodextrin (Scheme 1). In general, the reaction was carried out by the *in situ* formation of the β -CD complex of the aldehyde in water followed by the addition of 2-aminothiophenol and stirring at 60-65 °C to gave the corresponding 2-phenylbenzo[d]thiazole in high yield (81%) (Table 1, entry 1). These reactions proceeded efficiently without the need of any metal or acid catalyst. The reaction goes to completion in a short time (4–10 h). The reactions also take place with α -CD and γ -CD, with lesser yields, however, β -CD has been chosen as the mediator as it is inexpensive and easily accessible. Several examples illustrating this simple and practical methodology are summarized in Table 1. All the compounds were characterized by ^1H NMR, IR, and mass spectrometry. The catalytic activity of cyclodextrins for these reactions is established by the fact that no reaction was observed in the absence of cyclodextrin. Evidence for the complexation between the *p*-hydroxy benzaldehyde and cyclodextrin is supported by ^1H NMR spectroscopy. A comparison of the ^1H NMR spectra (DMSO- d_6) of β -CD, β -CD *p*-hydroxy benzaldehyde complex was studied and as indicated in Figure 3. All the reactions β -CD was recovered and reused.




Figure 2. Recyclability of β -CD.

After the reaction, the reaction mass was cooled and β -CD was filtered and washed with ice-cold water and dried. The recovered β -CD was further used with the same substrates as a catalyst and checked for the yields as well as the catalytic activity of the recovered β -CD, as shown in Figure 2. As we observed that the yields of benzimidazoles/benzothiazoles slightly decreased after three to fourth cycle as indicated in Figure 2.

Table 1. Synthesis of benzimidazoles/benzothiazoles.^a

Entry	Aldehyde	Product	Yield (%) ^b
1			81
2			80
3			81
4			79
5			79
6			78
7			77
8			80
9			80
10			79
11			80
12			78

55

Entry	Aldehyde	Product	Yield (%) ^b
13			79
14			77
15			76
16			79
17			78
18			79

^aReaction conditions: Aldehyde (1.0 mmol), 2-Amino thiophenol/1,2-Diamino benzene (1.0 mmol), β -Cyclodextrin (10 mol%), 60–65 °C. ^b Isolated yield.




Figure 3. ¹H NMR (300 MHz, DMSO-*d*₆) spectrum of (a) β -CD (b) *p*-hydroxy benzaldehyde (c) β -CD-*p*-hydroxy benzaldehyde inclusion complex.

Conclusion

In summary, we have developed an eco-friendly, one-pot protocol for the synthesis of 2-substituted benzothiazoles/benzimidazoles in good to excellent yields under neutral conditions promoted by β -cyclodextrin in aqueous medium. This simple and novel methodology will be useful to green chemistry with some advantage that the reaction excludes non-toxic, moisture sensitive or hazardous catalysts and elevated reaction temperatures, longer reaction times, and the catalyst β -CD is economically viable, readily available, easily handling.

Experimental Section

General experimental procedure for the synthesis of 2-substituted/benzothiazoles using β -cyclodextrin: β -Cyclodextrin (10 mol %) was dissolved in water (10 ml), and to

this clear solution, aldehyde was added, stirred for 15 min, followed by the addition of 1,2-diamino benzene/2-amino thiophenol (1.0 mmol). The reaction mixture was heated at 60–65 °C until completion of the reaction as indicated by TLC. The reaction mixture was cooled to 5 °C and β -cyclodextrin was filtered. The aqueous layer was extracted with ethyl acetate (3 x 10 ml). The combined organic layers were washed with water, saturated brine solution, and dried over anhydrous Na₂SO₄. The combined organic layers were evaporated under reduced pressure and the resulting crude product was purified by column chromatography using ethyl acetate and hexane (1:9) as an eluent. The identity and purity of the products were confirmed by ¹H, ¹³C NMR, and mass spectra.

2-Phenylbenzo[d]thiazole (Table 1, Entry 1); ¹H NMR (300 MHz, CDCl₃) δ = 8.11–8.07 (m, 3H), 7.90 (d, 1H, *J* = 7.9 Hz), 7.52–7.47 (m, 3H), 7.42–7.36 (m, 2H); ¹³C NMR (50 MHz, CDCl₃) δ = 130.93, 128.98, 127.50, 126.27, 125.14, 123.18, 121.57; MS (ESI): *m/z* = 212 [M+H]⁺.

2-(4-bromophenyl)benzo[d]thiazole (Table 1, Entry 2); ¹H NMR (300 MHz, CDCl₃) δ = 8.08 (d, 1H, *J* = 8.1 Hz), 7.99–7.94 (m, 2H), 7.91 (d, 1H, *J* = 7.9 Hz), 7.65–7.61 (m, 2H), 7.53–7.48 (m, 1H), 7.43–7.38 (m, 1H); ¹³C NMR (50 MHz, CDCl₃) δ = 166.62, 154.04, 135.00, 132.18, 128.86, 126.46, 125.40, 123.28, 121.62, 132.18, 128.86, 126.46, 125.40, 123.28, 121.62; MS (ESI): *m/z* = 290 [M+2]⁺.

2-(4-fluorophenyl)benzo[d]thiazole (Table 1, Entry 3); ¹H NMR (300 MHz, CDCl₃) δ = 8.09–8.05 (m, 4H), 7.89 (d, 1H, *J* = 7.6 Hz), 7.49 (t, 1H, *J* = 7.1 Hz), 7.18 (t, 2H, *J* = 7.0 Hz); ¹³C NMR (50 MHz, CDCl₃) δ = 166.61, 153.91, 134.90, 129.44, 129.37, 126.31, 125.15, 123.06, 121.50, 116.12, 115.94; MS (ESI): *m/z* = 230 [M+H]⁺.

2-(2-methoxyphenyl)benzo[d]thiazole (Table 1, Entry 4); ¹H NMR (300 MHz, CDCl₃) δ = 8.53 (d, 1H, *J* = 1.8 Hz), 8.52 (d, 1H, *J* = 1.6 Hz), 8.09 (d, 1H, *J* = 8.2 Hz), 7.50 (d, 1H, *J* = 1.2 Hz), 7.49–7.44 (m, 2H), 7.38–7.35 (m, 2H), 4.06 (s, 3H); ¹³C NMR (50 MHz, CDCl₃) δ = 157.15, 152.09, 131.72, 129.45, 125.82, 124.51, 122.71, 121.13, 111.59; MS (ESI): *m/z* = 242 [M+H]⁺.

2-(2-bromophenyl)benzo[d]thiazole (Table 1, Entry 5); ¹H NMR (300 MHz, CDCl₃) δ = 8.15 (d, 1H, *J* = 7.9 Hz), 8.01–7.94 (m, 2H), 7.73 (d, 1H, *J* = 7.9 Hz), 7.56–7.30 (m, 4H); ¹³C NMR (50 MHz, CDCl₃) δ = 165.61, 152.50, 133.96, 132.07, 131.17, 127.48, 126.23, 125.41, 123.43, 121.34; MS (ESI): *m/z* = 290 [M+2]⁺.

4-(benzo[d]thiazol-2-yl)phenol (Table 1, Entry 6); ¹H NMR (300 MHz, CDCl₃) δ = 8.37 (s, 1H), 8.03–7.95 (m, 2H), 7.89–7.77 (m, 2H), 7.47 (t, 1H, *J* = 7.1 Hz), 7.36 (t, 1H, *J* = 6.9 Hz), 6.96–6.92 (m, 2H); ¹³C NMR (50 MHz, CDCl₃) δ = 167.16, 159.71, 153.28, 133.79, 128.31, 125.34, 123.97, 123.87, 121.66, 120.75, 115.32; MS (ESI): *m/z* = 228 [M+H]⁺.

4-(benzo[d]thiazol-2-yl)benzene-1,2-diol (Table 1, Entry 7); ¹H NMR (300 MHz, CDCl₃) δ = 7.22–7.15 (m, 2H), 7.10–7.04 (m, 2H), 7.00–6.93 (m, 2H), 6.85–6.79 (m, 1H), 5.27 (s, 2H); ¹³C NMR (50 MHz, CDCl₃) δ = 143.64, 128.20, 128.08, 127.81, 127.69, 127.62, 127.24, 126.94, 125.67, 36.94, 36.66, 31.91, 31.80, 30.16, 30.04, 29.71, 29.34, 29.24, 27.72, 27.64, 22.82, 22.68, 22.58, 14.11; MS (ESI): *m/z* = 244 [M+H]⁺.

2-(3,4,5-trimethoxyphenyl)benzo[d]thiazole (Table 1, Entry 8); ¹H NMR (300 MHz, CDCl₃) δ = 8.06 (d, 1H, *J* = 8.2 Hz), 7.89 (d, 1H, *J* = 7.6 Hz), 7.51–7.48 (m, 2H), 7.33 (s, 1H), 7.13 (s, 1H), 3.99 (s, 9H); ¹³C NMR (50 MHz, CDCl₃) δ = 153.89, 153.48, 134.83, 126.31, 125.09, 122.97, 121.48, 104.64, 60.94, 56.29; MS (ESI): *m/z* = 302 [M+H]⁺.

2-(1H-indol-3-yl)benzo[d]thiazole (Table 1, Entry 9); ¹H NMR (300 MHz, CDCl₃) δ = 8.94 (s, 1H), 8.44 (d, 1H, *J* = 7.1 Hz), 8.02 (d, 1H, *J* = 8.1 Hz), 7.93 (d, 1H, *J* = 2.8 Hz), 7.87 (d, 1H, *J* = 7.9 Hz), 7.48–7.27 (m, 5H); ¹³C NMR (50 MHz, CDCl₃) δ = 163.24, 153.61, 136.44, 133.78, 126.42, 126.05, 124.85, 124.19, 123.35, 121.98, 121.75, 121.29, 120.91, 112.24, 111.72; MS (ESI): *m/z* = 251 [M+H]⁺.

2-(3,5-dimethylphenyl)benzo[d]thiazole (Table 1, Entry 10); ¹H NMR (300 MHz, CDCl₃) δ = 7.52–7.45 (m, 2H), 7.41–7.33 (m, 2H), 7.29–7.25 (m, 1H), 7.19–7.05 (m, 2H), 2.58 (s, 3H), 2.38 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ = 139.9, 129.4, 128.8, 128.2, 123.6, 119.2, 117.9, 22.6, 21.2; ESI-MS: *m/z* = 240 [M+H]⁺.

2-phenyl-1H-imidazole (Table 1, Entry 11); ¹H NMR (300 MHz, CDCl₃) δ = 8.07 (d, 1H, *J* = 6.2 Hz), 7.68–7.64 (m, 3H), 7.49–7.44 (m, 2H), 7.29–7.27 (m, 2H), 7.10 (d, 1H, *J* = 6.8 Hz), 5.47 (s, 1H); ¹³C NMR (50 MHz, CDCl₃) δ = 151.52, 129.95, 129.25, 128.26, 126.35, 121.78; MS (ESI): *m/z* = 195 [M+H]⁺.

2-(2-methoxyphenyl)-1H-benzo[d]imidazole (Table 1, Entry 12); ¹H NMR (300 MHz, CDCl₃) δ = 8.01-7.98 (m, 5H), 6.93-6.90 (m, 4H), 3.86 (s, 3H); ¹³C NMR (50 MHz, CDCl₃) δ = 157.47, 156.38, 152.33, 143.03, 135.37, 132.26, 131.40, 128.33, 127.63, 122.44, 121.94, 120.70, 120.29, 119.60, 110.73, 109.83, 55.12, 55.03, 43.48; MS (ESI): *m/z* = 225 [M+H]⁺.

2-(4-ethoxyphenyl)-1H-benzo[d]imidazole (Table 1, Entry 13); ¹H NMR (300MHz, DMSO-d₆) δ = 7.59-7.55 (m, 2H), 7.25-7.14 (m, 3H), 6.77 (d, 1H, *J* = 8.3 Hz), 6.92-6.88 (m, 2H), 4.08-3.94 (q, 2H), 1.43 (t, 3H, *J* = 7.5 Hz); ¹³C NMR (300 MHz, DMSO-d₆): δ = 160.28, 158.50, 153.97, 143.09, 136.03, 130.66, 128.14, 127.11, 122.66, 119.71, 114.62, 110.32, 63.34, 14.80; MS (ESI): *m/z* = 239 [M+H]⁺.

2-(4-chlorophenyl)-1H-benzo[d]imidazole (Table 1, Entry 14); ¹H NMR (300 MHz, CDCl₃) δ = 7.57 (d, 1H, *J* = 7.6 Hz), 7.41 (d, 2H, *J* = 7.6 Hz), 7.32-7.20 (m, 3H), 7.12 (d, 1H, *J* = 7.6 Hz), 7.01 (d, 1H, *J* = 7.6 Hz); ¹³C NMR (50 MHz, CDCl₃) δ = 130.93, 128.98, 127.50, 126.27, 125.14, 123.18, 121.57; MS (ESI): *m/z* = 229 [M+H]⁺.

2-(2-chlorophenyl)-1H-benzo[d]imidazole (Table 1, Entry 15); ¹H NMR (300 MHz, CDCl₃) δ = 8.62 (s, 1H), 7.93 (d, 3H, *J* = 5.8 Hz), 7.47 (s, 2H), 7.25 (s, 1H), 6.70 (d, 1H, *J* = 8.3 Hz), 4.92 (s, 1H); ¹³C NMR (50 MHz, CDCl₃) δ = 158.20, 130.92, 128.96, 127.52, 126.25, 125.13, 123.17, 121.56; MS (ESI): *m/z* = 229 [M+H]⁺.

2-(4-nitrophenyl)-1H-benzo[d]imidazole (Table 1, Entry 16); ¹H NMR (300 MHz, CDCl₃) δ = 7.66-7.64 (m, 2H), 7.44-7.40 (m, 3H), 7.32-7.25 (m, 3H); ¹³C NMR (50 MHz, CDCl₃) δ = 160.27, 158.51, 153.96, 143.08, 136.00, 130.64, 128.12, 127.10, 122.62, 119.70, 114.63, 110.32; MS (ESI): *m/z* = 240 [M+H]⁺.

2-(p-tolyl)-1H-benzo[d]imidazole (Table 1, Entry 17); ¹H NMR (300 MHz, CDCl₃) δ = 8.12 (d, 4H, *J* = 8.3 Hz), 7.32 (d, 4H, *J* = 8.1 Hz), 3.13 (s, 1H), 2.44 (s, 3H); ¹³C NMR (50 MHz, CDCl₃) δ = 140.31, 137.77, 132.74, 129.77, 129.45, 128.81, 125.70, 123.20, 120.52, 110.45, 21.03; MS (ESI): *m/z* = 209 [M+H]⁺.

2-(4-methoxyphenyl)-1H-benzo[d]imidazole (Table 1, Entry 18); ¹H NMR (300 MHz, CDCl₃) δ = 8.11 (d, 1H, *J* = 8.6 Hz), 7.65-7.46 (m, 3H), 6.98-6.93 (m, 3H), 6.79 (d, 1H, *J* = 8.6 Hz), 3.73 (s, 3H); ¹³C NMR (50 MHz, CDCl₃) δ = 166.63, 164.10, 154.82, 132.97, 58.43; MS (ESI): *m/z* = 225 [M+H]⁺.

Acknowledgements

Brazilian authors (R. K. and N. L. C. D) thanks to Conselho Nacional de Desenvolvimento Científico e Tecnológico for BJT fellowship and the financial support Processos: 314140/2014-0 and 400706/2014-8 CNPq - Brazil). The authors thanks to Dr. Y. V. D. Nageswar, Chief Scientist in Indian Institute of Chemical Technology (IICT) Hyderabad, India for the spectroscopic analysis.

References

- (a) O. I. El-Sabbagh, M. M. Baraka, S. M. Ibrahim, C. Pannecouque, G. Andrei, R. Snoeck, J. Balzarini, A. A. Rashad, *Eur. J. Med. Chem.* 2009, **44**, 3746e3753; (b) V. Zaharia, A. Ignat, N. Palibroda, B. Ngameni, V. Kuete, C. N. Fokunang, M. L. Mougang, B. T. Ngadjui, *Eur. J. Med. Chem.* 2010, **45**, 5080e5085; (c) I. Hutchinson, S. A. Jennings, B. R. Vishnuvajjala, A. D. Westwell, M. F. G. Stevens, *J. Med. Chem.* 2002, **45**, 744e747.
- (a) J. S. Kim, B. Gatto, C. Yu, A. Liu, L. F. Liu, E. J. LaVoie, *J. Med. Chem.* 1996, **39**, 992; (b) A. Kamal, M. N. A. Khan, K. S. Reddy, K. Rohini, *Bioorg. Med. Chem.* 2007, **15**, 1004e1013; (c) R. B. Pathak, B. Jahan, S. C. Bahel, *Bokin Bobai* 1981, **9**, 477e480; (d) D. D. Erol, U. Calis, R. Demirdamar, N. Yulug, M. Ertan, *J. Pharm. Sci.* 1995, **84**, 462e465.
- (a) T. Roth, M. L. Morningstar, P. L. Boyer, S. H. Hughes, R. W. Jr. Buckheit, C. J. Michejda, *J. Med. Chem.* 1997, **40**, 4199; (b) F. Azam, B. A. El-Gnidi, I. A. Alkskas, M. A. Ahmed, *J. Enzym. Inhib. Med. Chem.* 2010, **25**, 818e826; (c) Y. Kumar, R. Green, K. Z.

- Boryska, D. D. Wise, L. L. Wotring, L. B. Townsend, *J. Med. Chem.* 1993, **36**, 3843e3848.
- M. J. Tebbe, W. A. Spitzer, F. Victor, S. C. Miller, C. C. Lee, T. R. Sattelberg, E. McKinney, C. J. Tang, *J. Med. Chem.* 1997, **40**, 3937.
- (a) D. I. Shah, M. Sharma, Y. Bansal, G. Bansal, M. Singh, *Eur. J. Med. Chem.* 2008, **43**, 1808; (b) R. N. Sharma, F. P. Xavier, K. K. Vasu, S. C. Chaturvedi, S. S. Pancholi, *J. Enzym. Inhib. Med. Chem.* 2009, **24**, 890e897.
- Y. Ogino, N. Ohtake, Y. Nagae, K. Matsuda, M. Moriya, M. Suga, M. Ishikawa, Y. Kanesaka, J. Ito Mitobe, T. Kanno, T. A. Ishiara, H. Iwaasa, T. Ohe, A. Kanatani, T. Fukami, *Bioorg. Med. Chem. Lett.* 2008, **18**, 5010.
- P. Ghosh, A. Mandal, *Catalysis Communications*. 2011, **12**, 744.
- V. Mirkhani, M. Moghadam, S. Tangestaninejad, H. Kargar, *Tetrahedron Lett.* 2006, **47**, 2129.
- B. Das, H. Holla, Y. Srinivas, *Tetrahedron Lett.* 2007, **48**, 61.
- K. R. Hornberger, G. M. Adjabeng, H. D. Dickson, R. G. Davis-Ward, *Tetrahedron Lett.* 2006, **47**, 5359.
- S. Lin, L. Yang, *Tetrahedron Lett.* 2005, **46**, 4315.
- P. L. Beaulieu, B. Haché, E. V. Moos, *Synthesis* 2003, **11**, 1683.
- R. N. Nadaf, S. A. Siddiqui, T. Daniel, R. J. Lahoti, K. V. Srinivasan, *J. Mol. Cat. A: Chem.* 2004, **214**, 155.
- D. Saha, A. Saha, B. C. Ranu, *Green Chem.* 2009, **11**, 733.
- (a) S. N. Murthy, B. Madhav, A. V. Kumar, K. R. Rao, Y. V. D. Nageswar, *Helv Chim. Acta.* 2009, **92**, 2118; (b) S. N. Murthy, B. Madhav, A. V. Kumar, K. R. Rao, Y. V. D. Nageswar, *Tetrahedron* 2009, **65**, 5251; (c) B. Madhav, S. N. Murthy, V. P. Reddy, K. R. Rao, Y. V. D. Nageswar, *Tetrahedron Lett.* 2009, **50**, 6025; (d) S. N. Murthy, B. Madhav, V. P. Reddy, Y. V. D. Nageswar, *Tetrahedron Lett.* 2010, **51**, 3649; (e) J. Shankar, K. Karnakar, B. Srinivas, Y. V. D. Nageswar, *Tetrahedron Lett.* 2010, **51**, 3938; (f) S. N. Murthy, B. Madhav, Y. V. D. Nageswar, *Tetrahedron Lett.* 2010, **51**, 5252; (g) K. Ramesh, S. N. Murthy, K. Karnakar, Y. V. D. Nageswar, *Tetrahedron Lett.* 2011, **52**, 3937; (h) K. Ramesh, S. N. Murthy, K. Karnakar, Y. V. D. Nageswar, *Tetrahedron Lett.* 2011, **52**, 4734; (i) B. S. P. Anil Kumar, B. Madhav, K. Harsha Vardhan Reddy, Y. V. D. Nageswar, *Tetrahedron Lett.* 2011, **52**, 2862; (j) K. Ramesh, S. N. Murthy, K. Karnakar, Y. V. D. Nageswar, K. Vijayalakshmi, B. L. A. Prabhavathi Devi, R. B. N. Prasad, *Tetrahedron Lett.* 2012, **53**, 1126; (k) K. Ramesh, B. Madhav, S. N. Murthy, Y. V. D. Nageswar, *Synth. Commun.* 2012, **42**, 258; (l) K. Ramesh, S. N. Murthy, Y. V. D. Nageswar, *Synth. Commun.* 2012, **42**, 2471; (m) K. Ramesh, S. N. Murthy, Y. V. D. Nageswar, *Tetrahedron Lett.* 2011, **52**, 2362; (n) S. S. Panda, S. C. Jain, *Synth. Comm.* 2011, **41**, 729.